Oxbryta Events

Muyiwa

...

Father, bongo player, and actual Oxbryta patient

Connect with the community

Sign up to join a community of sickle cell patients and caregivers and learn more about treatment options from a specialist at a webinar or live event near you.

Unfortunately there are currently no events that meet your search criteria.

Webinar

10/22/2022

12:30 PM ET

Jamal Jones Motorcycle Memory Ride Sickle Cell Awareness

Love Thy Neighbor Program, Inc.

Program Speaker:

Patricia Adams-Graves, MD

Medical Staff, Diggs-Kraus Sickle Cell Center, Regional One Health

Questions?

Call (732) 969-5000 x157

To register, please fill out the information below. These programs are for US residents only.

*Required field.



By submitting this form, you agree to allow Oxbryta and its agents to collect the information provided and to be contacted directly by an Oxbryta representative. Your information will not be used for any other purpose than for a representative to respond to your information request or for us to send you other updates if you have registered to receive them. Oxbryta will not sell, rent, or otherwise distribute your name and any personally identifiable information outside of Oxbryta and its agents. Oxbryta will only use your information in accordance with its Privacy Policy.

Cancel

Want to know more about a different kind of sickle cell treatment?

INDICATION

What is OXBRYTA?

OXBRYTA is a prescription medicine used for the treatment of sickle cell disease in adults and children 4 years of age and older.

It is not known if OXBRYTA is safe and effective in children with sickle cell disease below 4 years of age.

This indication is approved under accelerated approval based on increase in hemoglobin (Hb). Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trial(s).

IMPORTANT SAFETY INFORMATION

Do not take OXBRYTA if you or your child have had an allergic reaction to voxelotor or any of the ingredients in OXBRYTA. See the end of the patient leaflet for a list of the ingredients in OXBRYTA.

Before taking OXBRYTA, tell your healthcare provider about all of your medical conditions, including if you or your child:

  • have liver problems
  • are pregnant or plan to become pregnant. It is not known if OXBRYTA can harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if OXBRYTA can pass into your breastmilk and if it can harm your baby. Do not breastfeed during treatment with OXBRYTA and for at least 2 weeks after the last dose.

Tell your healthcare provider about all the medicines you or your child take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Some medicines may affect how OXBRYTA works. OXBRYTA may also affect how other medicines work and may affect the results of certain blood tests. Keep a list of all your medicines and show it to your healthcare provider.

What should I avoid while taking OXBRYTA?

Do not take St. John’s wort during treatment with OXBRYTA.

What are the possible side effects of OXBRYTA?

OXBRYTA can cause serious side effects, including:

Serious allergic reactions. Tell your healthcare provider or get emergency medical help right away if you get:

  • rash
  • hives
  • shortness of breath (difficult breathing)
  • swelling of the face

The most common side effects of OXBRYTA include:

  • headache
  • diarrhea
  • stomach-area (abdominal) pain
  • nausea
  • rash or hives
  • fever

The most common side effects of OXBRYTA in children ages 4 to less than 12 years of age include:

  • fever
  • vomiting
  • rash
  • stomach-area (abdominal) pain
  • diarrhea
  • headache

These are not all the possible side effects of OXBRYTA.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You may also report side effects to Global Blood Therapeutics at 1-833-428-4968 (1-833-GBT-4YOU).

Keep OXBRYTA and all medicines out of the reach of children.

Oxbryta and the GBT Logo are registered trademarks of Global Blood Therapeutics, Inc. All other trademarks are the property of their respective owners.

© 2022 Global Blood Therapeutics, Inc. All Rights Reserved. P-VOX-US-01348 v1

This site is intended for residents of the United States, Puerto Rico, and US territories.

MORE